Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHA:600436)

SHA:600436 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,770	1,488	1,159	2,496	7,097	5,168
Short-Term Investments	3,256	3,520	9,014	6,202	-	-
Trading Asset Securities	-	-	-	-	8.8	0.01
Cash & Short-Term Investments	5,026	5,008	10,173	8,698	7,106	5,168
Cash Growth	-45.38%	-50.78%	16.95%	22.42%	37.48%	21.23%
Accounts Receivable	1,088	894.43	1,021	859.49	673.3	574.34
Other Receivables	72.99	67.88	65.15	107.94	134.95	70.11
Receivables	1,161	962.31	1,086	967.43	808.25	644.45
Inventory	5,724	4,967	3,379	2,628	2,438	2,191
Prepaid Expenses	8.4	12.82	14.05	4.55	20.68	-
Other Current Assets	372.46	378.99	447.9	406.61	261.36	292.18
Total Current Assets	12,292	11,329	15,100	12,705	10,633	8,296
Property, Plant & Equipment	1,745	1,508	614.62	465.62	400.14	274.96
Long-Term Investments	4,093	870.45	631.98	673.7	799.87	979.2
Other Intangible Assets	266.48	273.1	291.09	319.37	220.96	259.38
Long-Term Deferred Tax Assets	134.72	155.5	187.31	167.26	166.98	85.41
Long-Term Deferred Charges	30.72	34.05	29.99	37.65	44.19	49.42
Other Long-Term Assets	147.68	3,370	225.4	235.41	255.59	261.16
Total Assets	18,709	17,540	17,080	14,604	12,521	10,206
Accounts Payable	507.52	480.01	667.92	464.9	386.99	239.94
Accrued Expenses	367.53	485.41	685.98	345.39	342.14	139.24
Short-Term Debt	832.1	892.79	989.93	970.96	775.79	718.38
Current Portion of Long-Term Debt	7.6	6.99	1.87	-	-	-
Current Portion of Leases	34.84	35.81	31.86	29.21	22.75	-
Current Income Taxes Payable	61.89	59.07	142.65	72.93	108.96	77.56
Current Unearned Revenue	166.36	270.81	237.1	468.57	326.56	283.75
Other Current Liabilities	1,225	142.92	125.8	158.22	173.9	341.46
Total Current Liabilities	3,203	2,374	2,883	2,510	2,137	1,800
Long-Term Debt	59.88	58.15	35.44	-	-	-
Long-Term Leases	136.43	154.58	107.29	108.8	86.67	-
Long-Term Unearned Revenue	26.21	26.68	17.67	17.01	20.24	14.68
Long-Term Deferred Tax Liabilities	2.06	0.33	30.02	61.09	74.52	47.47
Other Long-Term Liabilities	31.31	34.1	51.35	48.54	32.88	57.09
Total Liabilities	3,512	2,701	3,160	2,780	2,384	1,949
Common Stock	603.32	603.32	603.32	603.32	603.32	603.32
Additional Paid-In Capital	1,095	1,095	1,095	1,094	1,086	1,085
Retained Earnings	12,841	12,497	11,602	9,559	7,816	5,862
Comprehensive Income & Other	85.46	76.92	76.6	74.41	200.05	311.57
Total Common Equity	14,625	14,272	13,376	11,330	9,705	7,862
Minority Interest	572.29	567.01	544.17	493.97	432.07	394.39
Shareholders' Equity	15,197	14,839	13,920	11,824	10,138	8,257
Total Liabilities & Equity	18,709	17,540	17,080	14,604	12,521	10,206
Total Debt	1,071	1,148	1,166	1,109	885.21	718.38
Net Cash (Debt)	3,955	3,859	9,007	7,589	6,220	4,450
Net Cash Growth	-50.52%	-57.15%	18.67%	22.01%	39.78%	24.77%
Net Cash Per Share	6.55	6.39	14.94	12.59	10.31	7.37
Filing Date Shares Outstanding	603.32	603.32	603.32	603.32	603.32	603.32
Total Common Shares Outstanding	603.32	603.32	603.32	603.32	603.32	603.32
Working Capital	9,089	8,955	12,217	10,195	8,496	6,496
Book Value Per Share	24.24	23.66	22.17	18.78	16.09	13.03
Tangible Book Value	14,358	13,999	13,085	11,011	9,484	7,603
Tangible Book Value Per Share	23.80	23.20	21.69	18.25	15.72	12.60
Buildings	1,328	1,095	400.13	331.45	332.55	331.29
Machinery	384	368.02	345.33	324.4	300.25	263.39
Construction In Progress	347.95	314.85	157.19	60.78	14.94	1.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.